EPISODE · Dec 22, 2022 · 34 MIN
EASL Studio Podcast: Liver cancer in 2022: Wrap-up & outlook
from EASL Podcasts
Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss:why certain trials have failed whereas others have succeeded,what we have learned about the connection between overall survival and progression-free survival as endpoints, andhow the systemic therapy of HCC has evolved.FacultyProf. Peter Galle (Moderator)Prof. Bruno Sangro (Faculty)Dr Anna Saborowski (Faculty)Prof. Arndt Vogel (Faculty)Related episodesS2E15 – JHEP Live – The best animal model for HCC — lost in translationSpecial Edition: Highlights of the Liver Cancer Summit 2022Policy Dialogues Episode 3: Liver Cancer: The risk of ignoranceAll EASL Studio Podcasts are available on EASL Campus.
Embed this episode
What this episode covers
Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss: why certain trials have failed whereas others have succeeded,what we have learned about the connection between overall survival and progression-free survival as endpoints, andhow the systemic therapy of HCC has evolved.Faculty Prof. Peter Galle (Moderator)Prof. Bruno Sangro (Faculty)Dr Anna Saborowski (Faculty)Prof. Arndt Vogel (Faculty)Related episodes S2E15 – JHEP Live – T...
NOW PLAYING
EASL Studio Podcast: Liver cancer in 2022: Wrap-up & outlook
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.